← 治験一覧に戻る
非放射線学的軸性脊椎関節炎患者におけるセクキヌマブの有効性および安全性に関する研究
基本情報
- NCT ID
- NCT02696031
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 555
- 治験依頼者名
- Novartis
概要
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208
対象疾患
Non-radiographic Spondyloarthritis
介入
Secukinumab(DRUG)
Placebo(DRUG)
依頼者（Sponsor）
ノバルティスファーマ株式会社(INDUSTRY)